To evaluate the efficacy and safety of 85 ciclopirox nail lacquer in the treatment of onychomycosis, Loprox nail lacquer was applied to thirty onychomycosis with patients for 6 months.
Patients were allocated to three groups according to the percent involvement of nail plate. For clinical effectiveness changes of percent involvement of nail plate and side effects were evaluated monthly. Before and after treatment, KOH smears and fungal cultures were performed for the evaluation of mycologic cure. At the end of the treatment, global assessment as well as evaluations of tolerance and cosmetic acceptance were done by patients and clinician. These data were considered significant when the p value was less than 0.001 using t-test.
In groupⅠ(≤25% involvement), 18.7% involvement of the nail plate before treatment decreased to 3.75 after treatment.
Whereas 35.7% involvement before treatment in GroupⅡ(25-50% involvement) decreased to 6.4% after treatment(p<0.001). Mycologic cure rates were 55.6 in GroupⅠ and 26.7% in GroupⅡ, respectively. No local side effects such as itching, burning sensation or cutaneous irritation were noted during treatment. For global assessment, 100% of the patients and 96% of clinicians reported complete cure or improvement, whereas 96% of patients and 100% of clinicians answered excellent or good tolerance ; on the cosmetic acceptance, 92% of patients and 965 of clinicians evaluated excellent or good.
These results suggest that, if les than 50% of nail plates was involved, 8% ciclopirox nail lacquer would be very effective and safe for the treatment of onychomycosis.
|